CYTK
Price
$56.27
Change
+$0.39 (+0.70%)
Updated
Sep 16, 12:12 PM (EDT)
45 days until earnings call
VBIVQ
Price
$0.07
Change
-$0.01 (-14.29%)
Updated
Aug 7, 03:59 PM (EDT)
Ad is loading...

CYTK vs VBIVQ

Header iconCYTK vs VBIVQ Comparison
Open Charts CYTK vs VBIVQBanner chart's image
Cytokinetics
Price$56.27
Change+$0.39 (+0.70%)
Volume$100
CapitalizationN/A
VBI Vaccines, Inc. (CDA)
Price$0.07
Change-$0.01 (-14.29%)
Volume$338.47K
CapitalizationN/A
View a ticker or compare two or three
CYTK vs VBIVQ Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VBIVQ
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CYTK vs. VBIVQ commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and VBIVQ is a StrongSell.

COMPARISON
Comparison
Sep 16, 2024
Stock price -- (CYTK: $55.88 vs. VBIVQ: $0.02)
Brand notoriety: CYTK and VBIVQ are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 74% vs. VBIVQ: 1%
Market capitalization -- CYTK: $6.57B vs. VBIVQ: $458.92K
CYTK [@Biotechnology] is valued at $6.57B. VBIVQ’s [@Biotechnology] market capitalization is $458.92K. The market cap for tickers in the [@Biotechnology] industry ranges from $606.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileVBIVQ’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • VBIVQ’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than VBIVQ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 3 TA indicator(s) are bullish while VBIVQ’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 3 bullish, 5 bearish.
  • VBIVQ’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, VBIVQ is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а +3.31% price change this week, while VBIVQ (@Biotechnology) price change was -11.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.05%. For the same industry, the average monthly price growth was +4.21%, and the average quarterly price growth was -1.79%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 31, 2024.

Industries' Descriptions

@Biotechnology (+2.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($6.58B) has a higher market cap than VBIVQ($459K). CYTK YTD gains are higher at: -33.070 vs. VBIVQ (-97.277).
CYTKVBIVQCYTK / VBIVQ
Capitalization6.58B459K1,432,462%
EBITDA-459.67MN/A-
Gain YTD-33.070-97.27734%
P/E RatioN/AN/A-
Revenue3.13MN/A-
Total Cash1.06BN/A-
Total Debt790MN/A-
FUNDAMENTALS RATINGS
CYTK vs VBIVQ: Fundamental Ratings
CYTK
VBIVQ
OUTLOOK RATING
1..100
7450
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
45100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4998
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VBIVQ's Valuation (34) in the Biotechnology industry is significantly better than the same rating for CYTK (100). This means that VBIVQ’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for VBIVQ (100). This means that CYTK’s stock grew somewhat faster than VBIVQ’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as VBIVQ (100). This means that CYTK’s stock grew similarly to VBIVQ’s over the last 12 months.

CYTK's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for VBIVQ (98). This means that CYTK’s stock grew somewhat faster than VBIVQ’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for VBIVQ (100). This means that CYTK’s stock grew significantly faster than VBIVQ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKVBIVQ
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 5 days ago
88%
Declines
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VBIVQ
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LQDI26.620.13
+0.47%
iShares Inflation Hedged Corp Bd ETF
ZECP30.430.14
+0.46%
Zacks Earnings Consistent ETF
VEMY27.390.10
+0.38%
Virtus Stone Harbor Emr Mkt Hi Yld BdETF
KSA41.250.04
+0.10%
iShares MSCI Saudi Arabia ETF
IHI59.42-0.06
-0.10%
iShares US Medical Devices ETF

VBIVQ and

Correlation & Price change

A.I.dvisor indicates that over the last year, VBIVQ has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if VBIVQ jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIVQ
1D Price
Change %
VBIVQ100%
-5.88%
MDGL - VBIVQ
56%
Loosely correlated
+3.00%
AXON - VBIVQ
48%
Loosely correlated
-1.27%
CYTK - VBIVQ
44%
Loosely correlated
+3.37%
ORMP - VBIVQ
42%
Loosely correlated
+5.51%
VERA - VBIVQ
37%
Loosely correlated
+5.19%
More